M. Guillemineau et al. / Carbohydrate Research 345 (2010) 2723–2730
2727
(8.5 mL), the reaction mixture was stirred at rt for 1 h and deionized
with Dowex 50 (H+) resin. The resin was filtered off, washed with
MeOH(25 mL)andthecombinedfiltrateandwashingswereconcen-
trated yielding pure glycolipid analogue 1 (74 mg, 94%) as a white
30.4, 30.1, 27.5, 23.7 (NCH2(CH2)10CH3), 25.2 (C-6), 14.5
(N(CH2)11CH3). HRESIMS calcd for C21H39O5N3SNa [M+Na]+:
468.2508, found: 498.2505.
amorphous powder. [a]
+8.0 (c 1.0, MeOH). 1H NMR (400 MHz,
D
1.5. 1-Octadecane-4-(6-thio-b-
[1,2,3]-triazole (4) and 1-octadecane-4-(6-thio-b-
D
-galactopyranosyloxymethyl)-
-galacto-
CD3OD): d 4.18 (d, 1H, J = 7.2 Hz, H-1), 3.91 (d, 1H, J = 2.1 Hz, H-4),
3.85 (m, 1H, OCHaHb(CH2)10CH3), 3.55 (m, 1H, OCHaHb(CH2)10CH3),
3.48–3.41 (m, 3H, H-2, H-3, H-5), 2.79 (dd, 1H, J = 7.3, 13.6 Hz,
H-6a), 2.66 (dd, 1H, J = 6.6, 13.6 Hz, H-6b), 1.62 (2H, m,
OCH2CH2(CH2)9CH3), 1.28 (m, 18H, OCH2CH2(CH2)9CH3), 0.89 (t,
3H, J = 6.6 Hz, O(CH2)11CH3). 13C NMR (100 MHz, CD3OD): d 105
(C-1), 78.0 (C-5), 75.0 (C-3), 72.4 (C-2), 71.0 (OCH2(CH2)10CH3),
70.3 (C-4), 33.1, 30.9, 30.8, 30.6, 30.5, 27.1, 23.7 (OCH2(CH2)10CH3),
25.2 (C-6), 14.5 (O(CH2)11CH3). HRESIMS calcd for C18H40NO5S
[M+NH4]+: 382.2627, found: 382.2637.
D
pyranosyloxymethyl)-[1,2,3]-triazole disulfide (15)
Sodium (7 mg, 0.304 mmol, 4 equiv) was added to a solution of
peracetate 14 (53 mg, 76 lmol, 1 equiv) in anhyd MeOH (7.6 mL)
and the reaction was left to proceed (1.5 h) and worked up as de-
scribed Section 1.2 for the preparation of compound 1. After evap-
oration of the solvent, the mixture (35 mg, 88%, 4/15 = 9:1
estimated by 1H NMR) of glycolipid analogue 4 and disulfide 15
was obtained as an amorphous powder. For analytical purpose,
these two products were separated by column chromatography
(MeOH–CH2Cl2, 8:92).
1.3. Octadecyl 6-thio-b-D-galactopyranoside (2)
Sodium (11.2 mg, 0.486 mmol, 2 equiv) was added to a solution
of peracetate 9 (150 mg, 0.243 mmol, 1 equiv) in anhyd MeOH
(2.5 mL) and the reaction was left to proceed (2 h) and worked up
as described Section 1.2 for the preparation of compound 1.
Glycolipid analogue 2 (80 mg, 73%) was obtained pure as a white
1.5.1. Analytical data for thiol 4
[a
]
D
ꢁ10.0 (c 1.0, 9:1.0 CHCl3–MeOH). 1H NMR (400 MHz, 9:1
CDCl3–CD3OD): d 7.57 (s, 1H, @CH), 4.92 (d, 1H, J = 12.2 Hz, OCHaHb),
4.67 (d, 1H, J = 12.2 Hz, OCHaHb), 4.30–4.22 (m, 3H, H-1,
NCH2(CH2)16CH3), 3.90 (d, 1H, J = 2.6 Hz, H-4), 3.56–3.44 (m, 2H,
H-2, H-3), 3.40 (t, 1H, J = 7.0 Hz, H-5), 2.82 (dd, 1H, J = 7.3, 13.8 Hz,
H-6a), 2.67 (dd, 1H, J = 6.4, 13.7 Hz, H-6b), 1.81 (t, 2H, J = 6.8 Hz,
NCH2CH2(CH2)15CH3), 1.28–1.10 (m, 30H, NCH2CH2(CH2)15CH3),
0.79 (t, 3H, J = 6.6 Hz, N(CH2)17CH3). 13C NMR (100 MHz, 9:1
CDCl3–CD3OD): d 144.0 (C@CH), 122.7 (C@CH), 102.6 (C-1), 76.6
(C-5), 73.4 (C-3), 71.1 (C-2), 68.6 (C-4), 62.1 (OCH2), 50.5
(NCH2(CH2)16CH3), 31.9, 30.2, 29.6, 29.5, 29.3, 28.9, 26.4, 22.6
(NCH2(CH2)16CH3), 24.4 (C-6), 14.0 (N(CH2)17CH3). HRESIMS calcd
for C27H51O5SN3Na [M+Na]+: 552.3447, found: 552.3461.
amorphous powder. [
a]
ꢁ9.5 (c 1.0, 9:1 CHCl3–MeOH). 1H NMR
D
(400 MHz, 9:1 CDCl3–CD3OD): d 4.14 (m, 1H, H-1), 3.91 (s, 1H,
H-4), 3.83 (m, 2H, OCHaHb(CH2)16CH3), 3.54–3.43 (m, 3H, H-2, H-3,
OCHaHb(CH2)16CH3), 3.39 (t, 1H, J = 7.0 Hz, H-5), 2.81 (m, 1H,
H-6a), 2.65 (dd, 1H, J = 6.7, 14.3 Hz, H-6b), 1.56 (m, 2H,
OCH2CH2(CH2)15CH3), 1.33–1.10 (m, 30H, OCH2CH2(CH2)15CH3),
0.80 (t, 3H, J = 6.4 Hz, O(CH2)17CH3). 1H NMR (400 MHz, DMSO-d6):
d 4.81 (d, 1H, J = 4.2 Hz, OH-2), 4.71, (d, 1H, J = 5.0 Hz, OH-3), 4.51
(d, 1H, J = 4.8 Hz, OH-4), 4.04 (d, 1H, J = 7.1 Hz, H-1), 3.74–3.65 (m,
2H, H-4, OCHaHb(CH2)16CH3), 3.40 (m, 1H, OCHaHb(CH2)16CH3),
3.34–3.29 (m, 1H, H-5), 3.27–3.19 (m, 2H, H-2, H-3), 2.67–2.54 (m,
2H, H-6a, H-6b), 2.18 (t, 1H, J = 8.9 Hz, SH), 1.50 (m, 2H,
OCH2CH2(CH2)15CH3), 1.33–1.18 (m, 30H, OCH2CH2(CH2)15CH3),
0.84 (t, 3H, J = 6.5 Hz, O(CH2)17CH3). 13C NMR (100 MHz, 9:1
CDCl3–CD3OD): d 103.0 (C-1), 76.4 (C-5), 73.4 (C-3), 71.3 (C-2),
70.2 (OCH2(CH2)16CH3), 68.7 (C-4), 31.8, 29.6, 29.5, 29.3, 29.2, 25.8,
24.5, 22.6 (OCH2(CH2)16CH3), 24.3 (C-6), 14.0 (O(CH2)17CH3). 13C
NMR (100 MHz, DMSO-d6): d 103.4 (C-1), 76.0 (C-5), 73.3 (C-3),
70.3 (C-2), 68.6 (OCH2(CH2)16CH3), 68.3 (C-4), 31.3, 29.3, 29.0, 28.9,
28.7, 25.5, 22.1 (OCH2(CH2)16CH3), 24.3 (C-6), 13.9 (O(CH2)17CH3).
1.5.2. Analytical data for disulfide 15
[a
]
D
ꢁ12.0 (c 0.3, 9:1 CHCl3–MeOH). 1H NMR (400 MHz, 9:1
CDCl3–CD3OD): d 7.59 (s, 2H, @CH), 4.94 (d, 2H, J = 12.3 Hz,
OCHaHb), 4.67 (d, 2H, J = 12.2 Hz, OCHaHb), 4.30 (d, 2H, J = 7.1 Hz,
H-1), 4.25 (t, 2H, J = 7.2 Hz, NCH2(CH2)16CH3), 3.87 (s, 2H, H-4),
3.67 (t, 2H, J = 6.7 Hz, H-5), 3.58–3.49 (m, 4H, H-2, H-3), 3.05 (dd,
2H, J = 7.5, 14.0 Hz, H-6a), 2.96 (dd, 2H, J = 5.8, 13.8 Hz, H-6b),
1.81 (t, 4H, J = 6.8 Hz, NCH2CH2(CH2)15CH3), 1.30–1.13 (m, 60H,
NCH2CH2(CH2)15CH3), 0.81 (t, 6H, J = 6.6 Hz, N(CH2)17CH3). 13C
NMR (100 MHz, 9:1 CDCl3–CD3OD): d 143.9 (C@CH), 122.8 (C@CH),
102.5 (C-1), 73.5 (C-5), 73.3 (C-3), 71.0 (C-2), 69.1 (C-4), 62.0
(OCH2), 50.4 (NCH2(CH2)16CH3), 39.4 (C-6), 31.8, 30.1, 29.6, 29.5,
29.3, 29.2, 28.9, 26.4, 22.6 (NCH2(CH2)16CH3), 14.0 (N(CH2)17CH3).
HRESIMS calcd for C54H101O10S2N6 [M+H]+: 1057.7021, found:
1057.7053.
HRESIMS calcd for
466.3596.
C
24H52NO5S [M+NH4]+: 466.3566, found:
1.4. 1-Dodecane-4-(6-thio-b-D-galactopyranosyloxymethyl)-
[1,2,3]-triazole (3)
Sodium (11 mg, 0.497 mmol, 4 equiv) was added to a solution of
peracetate 13 (76 mg, 0.124 mmol, 1 equiv) in anhyd MeOH
(12 mL) and the reaction was left to proceed (1 h) and worked up
as described Section 1.2 for the preparation of compound 1. Glyco-
lipid analogue 3 (55 mg, quant.) was obtained pure as a slightly
1.6. 6-S-Acetyl-6-thio-
a,b-D-galactopyranose (6)
The known25 1:2,3:4-di-O-isopropylidene-6-S-acetyl-6-thio-
a
,b- -galactopyranose 5 (1.01 g, 3.18 mmol) was dissolved in a
D
mixture of 2:3:5 H2O–AcOH–TFA (30 mL) and left at rt for 1 h.
The mixture was diluted with toluene (30 mL), solvents were evap-
orated and the residue was co-concentrated with toluene (2 ꢂ
30 mL). Chromatography (EtOAc–MeOH–H2O, 90:6:4) of the resi-
yellowish foam. [
a
]
D
ꢁ4.5 (c 1.0, MeOH). 1H NMR (400 MHz,
CD3OD): d 8.01 (s, 1H, @CH), 4.95 (d, 1H, J = 12.5 Hz, OCHaHb),
4.77 (d, 1H, J = 12.5 Hz, OCHaHb), 4.42–4.32 (m, 3H, H-1,
NCH2(CH2)10CH3, 3.92 (d, 1H, J = 2.6 Hz, H-4), 3.57–3.43 (m, 3H,
H-2, H-3, H-5), 2.81 (dd, 1H, J = 7.2, 13.6 Hz, H-6a), 2.67 (dd, 1H,
J = 6.6, 13.6 Hz, H-6b), 1.88 (t, 2H, J = 7.2 Hz, NCH2CH2(CH2)9CH3),
1.38–1.22 (m, 18H, NCH2CH2(CH2)9CH3), 0.88 (t, 3H, J = 6.6 Hz,
due gave hemiacetal 6 (718 mg, 95%,
1H NMR (400 MHz, CD3OD): d 5.09 (d, 1H, J = 3.2 Hz, H-1
(dd, 1H, J = 3.7, 3.8 Hz, H-1b), 3.98 (t, 1H, J = 6.7 Hz, H-5
(d, 1H, J = 1.7 Hz, H-4
, H-3 ), 3.49 (td, 1H, J = 7.3, 0.9 Hz, H-5b), 3.45–3.39 (m, 2H,
H-2b, H-3b), 3.19–3.02 (m, 4H, H-6 ,b), 2.31 (s, 6H, SCOCH3- ,b).
13C NMR (100 MHz, CD3OD): d 197.2 (C@O), 98.7 (C-1b), 94.2 (C-
a/b ratio 1:1) as a white foam.
a
), 4.38
a), 3.83
a
), 3.78 (s, 1H, H-4b), 3.75–3.67 (m, 2H, H-
N(CH2)11CH3). 13C NMR (100 MHz, CD3OD):
d
145.7 (C@CH),
2a
a
125.2 (C@CH), 104.2 (C-1), 78.1 (C-5), 74.8 (C-3), 72.2 (C-2), 70.2
(C-4), 63.2 (OCH2), 51.4 (NCH2(CH2)10CH3), 33.0, 31.3, 30.7, 30.6,
a
a